Ruconest
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Conestat alfa
- Used in
- Blood, clotting and anaemia
- Made by
- Pharming Group N.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Pharming Group N.V. |
|---|---|
| Active substance | Conestat alfa |
| Used in | Blood, clotting and anaemia |
| Classification | B06AC04 · Blood, clotting and anaemia |
| Authorised on | 2010-10-28 |
| Last updated by the regulator | 2026-05-20 |
| EMA product number | EMEA/H/C/001223 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).